Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Does CheckMate 026 Take Bristol Out Of The End Game?

Executive Summary

Failure of Bristol's Opdivo in patients with lower expression of PD-L-1 biomarker gives Merck's Keytruda a huge advantage in first-line lung cancer, and leaves market-leading Bristol to wait for combination data.

Advertisement

Related Content

Merck's Keytruda Enjoys Clean Sweep In Lung Cancer, At Bristol's Expense
J.P. Morgan Notebook Day 2: Bristol Humbled By Competition, Sanofi’s Sarilumab Ready For Review, Justifying Spinraza’s Price And More
Merck's Keytruda Chemo-Combo Data Has Big Implications For Future Of Immuno-Oncology
'Total Disaster' In First-Line Lung Cancer For BMS's Opdivo
ESMO Preview: Opdivo Under Pressure
Merck Defends Its Offensive Strategy For Keytruda
Bristol Should Have Opdivo First-Line Lung Cancer Data In Weeks
Bristol's Oncology Strategy: Cover All The Bases To Keep The Lead
Merck Oncology Strategy: With First-Line Lung Data, A New Day Dawns For Keytruda
Merck Is Finding PD-L1 Testing Is Helping Keytruda

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC097076

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel